Eloralintide
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Eli Lilly · Phase 2 · Recruiting · Enrollment 400
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Macupatide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Eloralintide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Macupatide Dose 1 + Eloralintide Dose 1 | n/r | n/r | n/r | n/r | n/r |
| Eloralintide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Macupatide Dose 1 + Eloralintide Dose 2 | n/r | n/r | n/r | n/r | n/r |
| Eloralintide Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Macupatide Dose 2 + Eloralintide Dose 3 | n/r | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.